Trial Profile
An open-label,single-arm trial of HIPEC combined with Apatinib in patients with advanced peritoneal implantation tumor
Status:
Suspended
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Colon cancer; Gastric cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 14 Aug 2018 Status changed from recruiting to suspended.
- 27 Nov 2017 New trial record